tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFs
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA

RNXT Stock Latest News

RenovoRx price target raised to $11.50 from $11 at Ascendiant
The FlyRenovoRx price target raised to $11.50 from $11 at Ascendiant
7d ago
RNXT
RenovoRx Buy Rating: Promising RenovoCath Adoption and TIGeR-PaC Study Progress Drive Positive Outlook
PremiumRatings
RenovoRx Buy Rating: Promising RenovoCath Adoption and TIGeR-PaC Study Progress Drive Positive Outlook
24d ago
RNXT
RenovoRx’s Innovative Drug Delivery and Promising Clinical Trials Earn a Buy Rating
PremiumRatings
RenovoRx’s Innovative Drug Delivery and Promising Clinical Trials Earn a Buy Rating
26d ago
RNXT
RenovoRx Earnings Call: Positive Outlook Amid Growth
PremiumCompany Announcements
RenovoRx Earnings Call: Positive Outlook Amid Growth
27d ago
RNXT
RenovoRx Reports Promising Q1 2025 Financial Results
PremiumCompany Announcements
RenovoRx Reports Promising Q1 2025 Financial Results
28d ago
RNXT
RenovoRx Reports Strong Q1 2025 Financial Results
PremiumCompany AnnouncementsRenovoRx Reports Strong Q1 2025 Financial Results
28d ago
8K
RNXT
RenovoRx reports Q1 EPS (8c), consensus (8c)
Premium
The Fly
RenovoRx reports Q1 EPS (8c), consensus (8c)
28d ago
RNXT
RenovoRx announces Johns Hopkins initiated for TIGeR-PaC Phase 3 trial
Premium
The Fly
RenovoRx announces Johns Hopkins initiated for TIGeR-PaC Phase 3 trial
1M ago
RNXT
RenovoRx Reports Initial Revenue and Clinical Trial Progress
PremiumCompany Announcements
RenovoRx Reports Initial Revenue and Clinical Trial Progress
2M ago
RNXT
RenovoRx increases production of RenovoCath
PremiumThe Fly
RenovoRx increases production of RenovoCath
2M ago
RNXT
RenovoRx: Promising Phase 3 Study and Revenue Growth Drive Buy Rating
PremiumRatings
RenovoRx: Promising Phase 3 Study and Revenue Growth Drive Buy Rating
2M ago
RNXT
RenovoRx Delays Yearly Report Filing
PremiumCompany Announcements
RenovoRx Delays Yearly Report Filing
2M ago
RNXT
RenovoRx’s Innovative Approach to Pancreatic Cancer Treatment: A Promising Investment Opportunity
PremiumRatingsRenovoRx’s Innovative Approach to Pancreatic Cancer Treatment: A Promising Investment Opportunity
3M ago
RNXT
RenovoRx initiated with a Buy at H.C. Wainwright
Premium
The Fly
RenovoRx initiated with a Buy at H.C. Wainwright
3M ago
RNXT
RenovoRx advnaces RenovoCath commercialization
Premium
The Fly
RenovoRx advnaces RenovoCath commercialization
4M ago
RNXT
RenovoRx presents data from Trans-Arterial Micro-Perfusion therapy platform
PremiumThe Fly
RenovoRx presents data from Trans-Arterial Micro-Perfusion therapy platform
4M ago
RNXT
RenovoRx 11.52M share Spot Secondary priced at $1.05
PremiumThe Fly
RenovoRx 11.52M share Spot Secondary priced at $1.05
4M ago
RNXT
RenovoRx announces common stock offering, no amount given
PremiumThe Fly
RenovoRx announces common stock offering, no amount given
4M ago
RNXT
RenovoRx announces SCRI Oncology partners enrolling patients for trial
PremiumThe Fly
RenovoRx announces SCRI Oncology partners enrolling patients for trial
6M ago
RNXT
RenovoRx receives first purchase orders for FDA-cleared RenovoCath
PremiumThe FlyRenovoRx receives first purchase orders for FDA-cleared RenovoCath
6M ago
RNXT
RenovoRx announces NHCI is enrolling patients for Phase III TIGeR-PaC trial
Premium
The Fly
RenovoRx announces NHCI is enrolling patients for Phase III TIGeR-PaC trial
7M ago
RNXT
RenovoRx reports Q3 net loss $2.5M vs $1.4M last year
Premium
The Fly
RenovoRx reports Q3 net loss $2.5M vs $1.4M last year
7M ago
RNXT

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >